<DOC>
	<DOCNO>NCT00943670</DOCNO>
	<brief_summary>This multicenter , open-label , single-arm Phase II study design evaluate effect T-DM1 duration correct QT ( QTc ) interval patient HER2-positive locally advanced metastatic breast cancer make preliminary assessment regard safety , tolerability , efficacy combine T-DM1 pertuzumab patient early disease progression . The QT interval measure time start Q wave end T wave heart 's electrical cycle . The QTcF interval QT interval calculate use Fridericia 's correction ; QTcB interval QT interval calculate use Bazett 's correction .</brief_summary>
	<brief_title>Corrected QT Interval Effects Trastuzumab Emtansine ( T-DM1 ) Patients With Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Locally Advanced Metastatic Breast Cancer Safety Tolerability Combined T-DM1 Pertuzumab Patients With Early Disease Progression</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Histologically document , locally advanced , metastatic breast cancer ; measurable and/or nonmeasureable evaluable disease permit HER2positive disease History prior trastuzumab therapy Life expectancy ≥ 90 day assess investigator Negative urine pregnancy test ≤ 72 hour prior Cycle 1 Day 1 woman childbearing potential For patient childbearing potential , agreement use one highly effective form contraception two effective form contraception duration study treatment ( ) 4 month last dose TDM1 6 month last dose pertuzumab , applicable Any chemotherapy , hormonal therapy , radiotherapy , immunotherapy , biologic therapy treatment breast cancer within 2 week first study treatment Prior TDM1 pertuzumab therapy History intolerance ( Grade 34 infusion reaction ) and/or adverse event related trastuzumab Grade ≥ 2 ( base National Cancer Institute Common Terminology Criteria Adverse Events [ NCI CTCAE ] v3 ) peripheral neuropathy time within 3 week prior first study treatment Brain metastasis untreated progressive require type therapy , include radiation , surgery , and/or steroid , control symptom brain metastasis within 60 day prior first study treatment History cardiac disease , unstable angina , symptomatic congestive heart failure ( CHF ) ( Class ≥ II per New York Heart Associate [ NYHA ] guideline ) , myocardial infarction , ventricular arrhythmia ≤ 6 month prior Cycle 1 , Day 1 Implantable pacemaker automatic implantable cardioverter defibrillator Congenital long QT syndrome family history long QT syndrome Current uncontrolled hypertension Current treatment medication alter cardiac conduction ( e.g. , digitalis , betablockers , calcium channel blocker ) medication generally accept risk cause torsades de pointes ( TdP ) Current know active infection human immunodeficiency virus ( HIV ) , hepatitis B virus , hepatitis C virus Major surgical procedure significant traumatic injury within 28 day prior first study treatment , anticipation need major surgery course study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>MBC</keyword>
	<keyword>TDM1</keyword>
	<keyword>Armed Herceptin</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Trastuzumab emtansine</keyword>
</DOC>